CD274 and non-small cell lung carcinoma: Until toripalimab was approved for the treatment of advanced NSCLC, other domestic or foreign PD-(L)1 inhibitors approved for the treatment of advanced NSCLC were unlikely to be economical, such as camrelizumab, sugemalimab, and atezolizumab (27–29).